<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530126</url>
  </required_header>
  <id_info>
    <org_study_id>2005 - PDGF</org_study_id>
    <nct_id>NCT01530126</nct_id>
  </id_info>
  <brief_title>Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain</brief_title>
  <official_title>Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to evaluate the safety and effectiveness of Platelet Derived Growth
      Factor (PDGF) mixed with b tricalcium phosphate (BTCP) for the treatment of advanced
      periodontal osseous defects at 6 months of healing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This triple blind, prospective and parallel arm trial was conducted in subjects requiring
      surgical treatment of a periodontal osseous defect.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of CAL Gain</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Measurements for the rate of clinical attachment levels (CAL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Gingival Recession (GR)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Measurements in changes of gingival recession (GR)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>B-TCP +buffer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed in sodium acetate buffer only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-TCP + 0.3 mg/ml rhPDGF-BB in buffer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 0.3 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-TCP + 1.0 mg/ml rhPDGF-BB in buffer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 1.0 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>B-TCP + 0.3 mg/ml rhPDGF-BB in buffer</intervention_name>
    <description>B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.</description>
    <arm_group_label>B-TCP + 0.3 mg/ml rhPDGF-BB in buffer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>B-TCP + 1.0 mg/ml rhPDGF-BB in buffer</intervention_name>
    <description>B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.</description>
    <arm_group_label>B-TCP + 1.0 mg/ml rhPDGF-BB in buffer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>B-TCP +buffer</intervention_name>
    <description>B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.</description>
    <arm_group_label>B-TCP +buffer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  probing depth of 7mm or greater at baseline

          -  following debridement, 4mm or greater vertical bone defect depth with at least one
             intact bony wall

          -  sufficient keratinized tissue to allow complete tissue coverage of the defect

          -  a radiographic base of the defect at least 3mm coronal to the apex of the tooth

          -  no evidence of localized aggressive periodontitis

          -  smoke less than 1 pack of cigarettes per day

        Exclusion Criteria:

          -  failure to maintain adequate oral hygiene

          -  pregnant women or women intending to become pregnant

          -  history of oral cancer within last 6 months or HIV

          -  history within last year of periodontal surgery on study tooth

          -  study tooth mobility greater than 2

          -  study tooth exhibiting a class 3 furcation defect

          -  signs of untreated acute infection at the surgical site, apical pathology, root
             fracture, severe root irregularities, cemental pearls, cementoenamel junction (CEJ)
             projections not easily removed, untreated carious lesions at the CEJ or on the root
             surface, subgingival restorations or restorations with open margins at or below CEJ

          -  history within 6 months of weekly or more frequent use of smokeless chewing tobacco,
             pipe or cigar smoking, or more than 20 cigarettes a day

          -  allergy to yeast derived products

          -  investigational therapy within 30 days of surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Giannobile, DDS, DMedSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan School of Dentistry</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Nevins M, Giannobile WV, McGuire MK, Kao RT, Mellonig JT, Hinrichs JE, McAllister BS, Murphy KS, McClain PK, Nevins ML, Paquette DW, Han TJ, Reddy MS, Lavin PT, Genco RJ, Lynch SE. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. J Periodontol. 2005 Dec;76(12):2205-15.</citation>
    <PMID>16332231</PMID>
  </results_reference>
  <results_reference>
    <citation>Nevins M, Kao RT, McGuire MK, McClain PK, Hinrichs JE, McAllister BS, Reddy MS, Nevins ML, Genco RJ, Lynch SE, Giannobile WV. Platelet-derived growth factor promotes periodontal regeneration in localized osseous defects: 36-month extension results from a randomized, controlled, double-masked clinical trial. J Periodontol. 2013 Apr;84(4):456-64. doi: 10.1902/jop.2012.120141. Epub 2012 May 21.</citation>
    <PMID>22612364</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <last_update_submitted>January 6, 2016</last_update_submitted>
  <last_update_submitted_qc>January 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>William Giannobile</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>periodontitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Becaplermin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

